Glenmark Pharmaceuticals Share Price
Sector: Biotechnology & Drugs
1408.70 +49.80 (3.66%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1360.70
Today’s High
1414.00
52 Week Low
985.60
52 Week High
1830.05
1407.60 +46.90 (3.45%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1359.90
Today’s High
1417.00
52 Week Low
985.20
52 Week High
1830.95
Key Metrics
- Market Cap (In Cr) 39678.85
- Beta 0.51
- Div. Yield (%) 0.18
- P/B 4.89
- TTM P/E -
- Peg Ratio -
- Sector P/E 26.62
- Open Price 1363.3
- Prev Close 1358.9
Glenmark Pharmaceuticals Analysis
Price Analysis
-
1 Week1.36%
-
3 Months-6.17%
-
6 Month-18.22%
-
YTD-15.44%
-
1 Year25.96%
Risk Meter
- 33% Low risk
- 33% Moderate risk
- 33% Balanced Risk
- 33% High risk
- 33% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 4
- 4
- 4
- 4
- Buy
- 2
- 2
- 2
- 1
- Hold
- 2
- 2
- 2
- 4
- Sell
- 1
- 1
- 1
- 1
- Strong Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Total
- 9
- 9
- 9
- 10
Glenmark Pharmaceuticals News
Mehta Equities' Riyank Arora suggests these stocks to buy or sell in short term
3 min read . 01 Apr 2025Why India’s top generics players are rushing to launch this diabetes drug
4 min read . 13 Mar 2025Glenmark Pharmaceuticals share price gains 5% post Q3 Results: Do you own it?
2 min read . 17 Feb 2025Glenmark Pharmaceuticals Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 11813.1
- Selling/ General/ Admin Expenses Total
- 3956.28
- Depreciation/ Amortization
- 581.91
- Other Operating Expenses Total
- 1658.45
- Total Operating Expense
- 12100.63
- Operating Income
- -287.53
- Net Income Before Taxes
- 36.5
- Net Income
- -1501.67
- Diluted Normalized EPS
- -46.58
- Period
- 2024
- Total Assets
- 14358.62
- Total Liabilities
- 6510.7
- Total Equity
- 7847.93
- Tangible Book Valueper Share Common Eq
- 230.82
- Period
- 2024
- Cashfrom Operating Activities
- -457.2
- Cashfrom Investing Activities
- 4560.89
- Cashfrom Financing Activities
- -3906.13
- Net Changein Cash
- 215.24
- Period
- 2023
- Total Revenue
- 11583.24
- Selling/ General/ Admin Expenses Total
- 3623.82
- Depreciation/ Amortization
- 569.17
- Other Operating Expenses Total
- 1626.06
- Total Operating Expense
- 11283.26
- Operating Income
- 299.98
- Net Income Before Taxes
- 239.84
- Net Income
- 297.25
- Diluted Normalized EPS
- 11.5
- Period
- 2023
- Total Assets
- 19371.68
- Total Liabilities
- 9897.75
- Total Equity
- 9473.92
- Tangible Book Valueper Share Common Eq
- 250.12
- Period
- 2023
- Cashfrom Operating Activities
- 626.06
- Cashfrom Investing Activities
- -528.49
- Cashfrom Financing Activities
- -77.46
- Net Changein Cash
- 32.5
- Period
- 2022
- Total Revenue
- 12304.9
- Selling/ General/ Admin Expenses Total
- 3374.22
- Depreciation/ Amortization
- 486.72
- Other Operating Expenses Total
- 1625.11
- Total Operating Expense
- 10725.77
- Operating Income
- 1579.14
- Net Income Before Taxes
- 1441.25
- Net Income
- 941.71
- Diluted Normalized EPS
- 39.91
- Period
- 2022
- Total Assets
- 17083.29
- Total Liabilities
- 7996.64
- Total Equity
- 9086.65
- Tangible Book Valueper Share Common Eq
- 241.04
- Period
- 2022
- Cashfrom Operating Activities
- 1108.65
- Cashfrom Investing Activities
- -333.28
- Cashfrom Financing Activities
- -520.49
- Net Changein Cash
- 272.43
- Period
- 2021
- Total Revenue
- 10943.93
- Selling/ General/ Admin Expenses Total
- 3242.35
- Depreciation/ Amortization
- 443.55
- Other Operating Expenses Total
- 1290.01
- Total Operating Expense
- 9258.56
- Operating Income
- 1685.37
- Net Income Before Taxes
- 1382.48
- Net Income
- 970.09
- Diluted Normalized EPS
- 33.26
- Period
- 2021
- Total Assets
- 15603.58
- Total Liabilities
- 8538.95
- Total Equity
- 7064.63
- Tangible Book Valueper Share Common Eq
- 167.62
- Period
- 2021
- Cashfrom Operating Activities
- 1131.21
- Cashfrom Investing Activities
- -675.24
- Cashfrom Financing Activities
- -441.78
- Net Changein Cash
- 27.82
- Period
- 2020
- Total Revenue
- 10640.97
- Selling/ General/ Admin Expenses Total
- 3254.42
- Depreciation/ Amortization
- 417.17
- Other Operating Expenses Total
- 1478.54
- Total Operating Expense
- 9326
- Operating Income
- 1314.97
- Net Income Before Taxes
- 1096.08
- Net Income
- 775.97
- Diluted Normalized EPS
- 26.7
- Period
- 2020
- Total Assets
- 14684.81
- Total Liabilities
- 8614.3
- Total Equity
- 6070.51
- Tangible Book Valueper Share Common Eq
- 137.8
- Period
- 2020
- Cashfrom Operating Activities
- 1392.41
- Cashfrom Investing Activities
- -783.52
- Cashfrom Financing Activities
- -444.66
- Net Changein Cash
- 174
- Period
- 2019
- Total Revenue
- 9865.47
- Selling/ General/ Admin Expenses Total
- 3188.08
- Depreciation/ Amortization
- 325.91
- Other Operating Expenses Total
- 1162.3
- Total Operating Expense
- 8438.39
- Operating Income
- 1427.08
- Net Income Before Taxes
- 1300.63
- Net Income
- 924.99
- Diluted Normalized EPS
- 28.55
- Period
- 2019
- Total Assets
- 13295.65
- Total Liabilities
- 7690.46
- Total Equity
- 5605.18
- Tangible Book Valueper Share Common Eq
- 137.09
- Period
- 2019
- Cashfrom Operating Activities
- 1324.17
- Cashfrom Investing Activities
- -698.99
- Cashfrom Financing Activities
- -738.74
- Net Changein Cash
- -297.08
- Period
- 2018
- Total Revenue
- 9103.07
- Selling/ General/ Admin Expenses Total
- 3624.5
- Depreciation/ Amortization
- 354.07
- Other Operating Expenses Total
- 309.1
- Total Operating Expense
- 7842.11
- Operating Income
- 1260.96
- Net Income Before Taxes
- 1066.8
- Net Income
- 774.19
- Diluted Normalized EPS
- 27.5
- Period
- 2018
- Total Assets
- 13020.96
- Total Liabilities
- 7431.9
- Total Equity
- 5589.05
- Tangible Book Valueper Share Common Eq
- 144.55
- Period
- 2018
- Cashfrom Operating Activities
- 1648.05
- Cashfrom Investing Activities
- -1013.34
- Cashfrom Financing Activities
- -468.5
- Net Changein Cash
- 176.99
- Period
- 2024-12-31
- Total Revenue
- 3387.55
- Selling/ General/ Admin Expenses Total
- 788.49
- Depreciation/ Amortization
- 122.74
- Other Operating Expenses Total
- 914.6
- Total Operating Expense
- 2910.06
- Operating Income
- 477.49
- Net Income Before Taxes
- 456.33
- Net Income
- 347.96
- Diluted Normalized EPS
- 12.33
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 3433.8
- Selling/ General/ Admin Expenses Total
- 786.56
- Depreciation/ Amortization
- 120.28
- Other Operating Expenses Total
- 975.24
- Total Operating Expense
- 2952.16
- Operating Income
- 481.63
- Net Income Before Taxes
- 472.57
- Net Income
- 354.21
- Diluted Normalized EPS
- 12.55
- Period
- 2024-09-30
- Total Assets
- 15235.34
- Total Liabilities
- 6789.68
- Total Equity
- 8445.66
- Tangible Book Valueper Share Common Eq
- 251.39
- Period
- 2024-09-30
- Cashfrom Operating Activities
- -783.02
- Cashfrom Investing Activities
- 516.31
- Cashfrom Financing Activities
- 440.85
- Net Changein Cash
- 160.63
- Period
- 2024-06-30
- Total Revenue
- 3244.19
- Selling/ General/ Admin Expenses Total
- 710.44
- Depreciation/ Amortization
- 117.79
- Other Operating Expenses Total
- 835.45
- Total Operating Expense
- 2773.76
- Operating Income
- 470.42
- Net Income Before Taxes
- 462.33
- Net Income
- 340.27
- Diluted Normalized EPS
- 12.06
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 3062.95
- Selling/ General/ Admin Expenses Total
- 700.95
- Depreciation/ Amortization
- 151.34
- Other Operating Expenses Total
- 862.13
- Total Operating Expense
- 3156.73
- Operating Income
- -93.78
- Net Income Before Taxes
- 530.83
- Net Income
- -1218.28
- Diluted Normalized EPS
- -33.78
- Period
- 2024-03-31
- Total Assets
- 14358.62
- Total Liabilities
- 6510.7
- Total Equity
- 7847.93
- Tangible Book Valueper Share Common Eq
- 230.82
- Period
- 2024-03-31
- Cashfrom Operating Activities
- -457.2
- Cashfrom Investing Activities
- 4560.89
- Cashfrom Financing Activities
- -3906.13
- Net Changein Cash
- 215.24
- Period
- 2023-12-31
- Total Revenue
- 2506.7
- Selling/ General/ Admin Expenses Total
- 753.04
- Depreciation/ Amortization
- 147.08
- Other Operating Expenses Total
- 930.06
- Total Operating Expense
- 2939.15
- Operating Income
- -432.45
- Net Income Before Taxes
- -521.38
- Net Income
- -351.37
- Diluted Normalized EPS
- -14.89
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 3207.38
- Selling/ General/ Admin Expenses Total
- 732.88
- Depreciation/ Amortization
- 141.45
- Other Operating Expenses Total
- 814.43
- Total Operating Expense
- 3211.97
- Operating Income
- -4.59
- Net Income Before Taxes
- -124.35
- Net Income
- -81.95
- Diluted Normalized EPS
- 0.38
- Period
- 2023-09-30
- Total Assets
- 20006.42
- Total Liabilities
- 10679.32
- Total Equity
- 9327.09
- Tangible Book Valueper Share Common Eq
- 244.55
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 295.65
- Cashfrom Investing Activities
- -398.94
- Cashfrom Financing Activities
- 233.89
- Net Changein Cash
- 122.91
- Period
- 2023-06-30
- Total Revenue
- 3036.07
- Selling/ General/ Admin Expenses Total
- 681.27
- Depreciation/ Amortization
- 142.04
- Other Operating Expenses Total
- 729.64
- Total Operating Expense
- 2792.78
- Operating Income
- 243.29
- Net Income Before Taxes
- 151.4
- Net Income
- 149.93
- Diluted Normalized EPS
- 1.71
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 11583.24
- Selling/ General/ Admin Expenses Total
- 2600.78
- Depreciation/ Amortization
- 569.17
- Other Operating Expenses Total
- 3089.92
- Total Operating Expense
- 11283.26
- Operating Income
- 299.98
- Net Income Before Taxes
- 239.84
- Net Income
- 297.25
- Diluted Normalized EPS
- 11.62
- Period
- 2023-03-31
- Total Assets
- 19371.68
- Total Liabilities
- 9897.75
- Total Equity
- 9473.92
- Tangible Book Valueper Share Common Eq
- 250.12
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 626.06
- Cashfrom Investing Activities
- -528.49
- Cashfrom Financing Activities
- -77.46
- Net Changein Cash
- 32.5
- Period
- 2022-12-31
- Total Revenue
- 3100.18
- Selling/ General/ Admin Expenses Total
- 707.46
- Depreciation/ Amortization
- 151.51
- Other Operating Expenses Total
- 852.24
- Total Operating Expense
- 2743.78
- Operating Income
- 356.4
- Net Income Before Taxes
- 329.86
- Net Income
- 272.58
- Diluted Normalized EPS
- 5.26
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Glenmark Pharmaceuticals Technical
Moving Average
SMA
- 5 Day1390.22
- 10 Day1377.95
- 20 Day1436.6
- 50 Day1414.01
- 100 Day1469.79
- 300 Day1530.17
Glenmark Pharmaceuticals Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Alkem Laboratories
- 5050
- 14.25
- 0.28
- 6440
- 4409.9
- 60374.92
- Glaxosmithkline Pharmaceutical
- 2850.1
- 46.05
- 1.64
- 3147.45
- 1869.14
- 48340.17
- Glenmark Pharmaceuticals
- 1408.7
- 49.8
- 3.66
- 1830.05
- 985.6
- 39678.85
- Biocon
- 320.65
- 8.65
- 2.77
- 404.6
- 262.3
- 38497.24
- Ipca Laboratories
- 1413.65
- -4.1
- -0.29
- 1757.65
- 1060.95
- 36055.34
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Alkem Laboratories
- 33.46
- 5.84
- 18.26
- 13.94
- Glaxosmithkline Pharmaceutical
- 68.5
- 26.71
- 20.45
- 12.25
- Glenmark Pharmaceuticals
- -
- 4.89
- 1.61
- 1.43
- Biocon
- 39.55
- 1.89
- 6.82
- 9.37
- Ipca Laboratories
- 54.89
- 5.69
- 14.98
- 12.25
Glenmark Pharmaceuticals Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 14-Feb-25
- Quarterly Results
- 14-Nov-24
- Quarterly Results
- 14-Aug-24
- Quarterly Results
- 24-May-24
- Audited Results & Final Dividend
- 14-Feb-24
- Quarterly Results
- 10-Nov-23
- Quarterly Results
- 11-Aug-23
- Quarterly Results
- 19-May-23
- Audited Results & Final Dividend
- 10-Feb-23
- Quarterly Results
- 11-Nov-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 27-Apr-25
- 26-Mar-25
- POM
- 27-Sept-24
- 30-Aug-24
- AGM
- 09-Nov-23
- 06-Oct-23
- POM
- 29-Sept-23
- 25-Aug-23
- AGM
- 06-Aug-23
- 05-Jul-23
- POM
- 16-Apr-23
- 15-Mar-23
- POM
- 16-May-22
- 13-Apr-22
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 24-May-24
- -
- 13-Sept-24
- 2.5
- 19-May-23
- -
- 18-Sept-23
- 2.5
- 30-May-22
- -
- 12-Sept-22
- 2.5
- 28-May-21
- -
- 08-Sept-21
- 2.5


